SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as investors discuss potential catalysts from upcoming earnings, including a possible S&P 500 inclusion and buybacks. Community sentiment is mixed, with some expressing concerns about the company's correlation to Bitcoin and the impact of potential dilutions. Some traders are anticipating volatility post-earnings, while others believe the stock is oversold and due for a bounce.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending downwards as investors react to increased AI spending plans and a large one-time tax charge, overshadowing otherwise positive earnings results. Despite a record-breaking bond offering, the community is debating whether this dip represents a buying opportunity or reflects deeper concerns about Meta's capital expenditures. Some traders are closely watching key support levels and potential for a rebound, while others express skepticism about the long-term profitability of Meta's AI investments.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

RDDT is trending as investors brace for its earnings report, with the central focus being ad revenue and AI partnerships. Community members are weighing the potential for a significant post-earnings move, drawing comparisons to META's recent performance, while also highlighting high short interest as a possible catalyst for a squeeze. Some traders express caution about the stock's valuation and potential for a selloff if earnings disappoint.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending downwards, with the community expressing concerns about recent price action and continued stock dilution; some are questioning the company's overall strategy and the credibility of bullish forecasts, while others remain optimistic about the long-term potential of Ethereum and BMNR's accumulation strategy.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is trending amid buyout speculation and renewed interest from SpaceX, driving community excitement about a potential bidding war. The community is buzzing about possible high buyout figures and the implications for existing partnerships, including the Apple deal. Discussions also involve Globalstar's spectrum value and potential combinations with other industry players.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

AAPL is trending as investors anticipate upcoming earnings, with some expecting a significant move in either direction. Community members are actively discussing potential outcomes and strategizing based on technical analysis and unusual options activity. The broader tech sector and potential AI developments remain a key focus for Apple's future growth.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending amid speculation of a potential acquisition, fueled by a recent report suggesting the company is in talks for a significant deal. The community is actively discussing potential buyout prices and speculating on which pharmaceutical company could be the acquirer, with some pointing to the company's oncology pipeline as a key attraction. Despite the positive price movement, some investors remain cautious, citing upcoming earnings and potential legal liabilities.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle's stock is trending downwards as investors react to concerns about slowing revenue growth and declining traffic, particularly among younger, lower-income consumers. The community is discussing the impact of these trends on the company's future, with some suggesting the need for strategic changes and others viewing the dip as a buying opportunity. There is also debate around the value proposition offered by Chipotle compared to competitors amidst rising costs.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending as investors anticipate its upcoming earnings report, focusing on the performance of AWS and its AI initiatives. Community sentiment appears mixed, with some expressing concerns about AWS growth and profitability, while others are optimistic about a potential breakout. The layoffs, framed as a strategic move towards AI, are also being heavily discussed.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent BioSolutions is trending as the community discusses a potential short squeeze and re-evaluation after a robust third quarter and raised FY25 EBITDA guidance, with some anticipating analyst upgrades and significant price movement. Bullish investors are expressing confidence in the company's fundamentals, while others debate potential resistance levels and optimal strategies. High trading volume and positive cash flow reports are also contributing to the heightened interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN...

Analysts on Monday expressed divergent opinions on vaccine company Valneva SE (VALN) after the firm said that the United States Food and Drug Administration (FDA) has suspended the license for its Chikungunya vaccine Ixchiq. Shares of Valneva tumbled over 19% on Monday.Jefferies analyst Maury Raycroft lowered the firm's price target on Valneva to $14 from $18 while keeping a ‘Buy’ rating on the shares following the news. The firm, which thinks there is some potential risk for ex-U.S. regulators to change their stance on Ixchiq licensure, added that Ixchiq is "not a major revenue driver" in the near term, according to TheFly.H.C. Wainwright analyst Brandon Folkes, meanwhile, reiterated a ‘Buy’ rating on Valneva. Despite the FDA's decision, Valneva has not revised its revenue guidance for 2025, the analyst noted. The stock selloff on Monday offers an attractive entry for investors who are constructive on a potential positive readout for VLA15, the company’s investigational Lyme disease vaccine, later this year, contends H.C. Wainwright. The firm views the selloff as overdone and keeps an $18 price target on Valneva, TheFly noted.On Stocktwits, retail sentiment around Valneva remained within ‘bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_25_at_12_45_54_PM_png_bbe73f8bfa.webp" alt="VALN's Sentiment Meter and Message Volume as of 12:45 p.m. ET on Aug. 25, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>VALN's Sentiment Meter and Message Volume as of 12:45 p.m. ET on Aug. 25, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user remains hopeful about the company getting acquired.<stembedurl>https://stocktwits.com/Papusa/message/626441643</stembedurl>Another, meanwhile, said that they are cutting their risk.<stembedurl>https://stocktwits.com/nroberts7/message/626439114</stembedurl>Valneva <a target="_blank" rel="noopener noreferrer nofollow" href="https://valneva.com/wp-content/uploads/2025/08/2025_08_25_FDA_IXCHIQ_Update_PR_EN_Final2.pdf">said</a> on Monday that the FDA suspended the license for Ixchiq in the U.S., citing four new reports of serious adverse events consistent with chikungunya-like illness. The suspension, it said, is effective immediately and requires the company to stop shipping and selling Ixchiq in the U.S.All four cases occurred outside the U.S., the company said. While three cases occurred in individuals aged 70 to 82 years, one case occurred in a 55-year-old individual. The company also said that an 82-year-old was hospitalized and discharged after two days.The firm said it believes all cases describe symptoms consistent with those reported during clinical trials, but added that it is continuing to investigate these cases in detail and will pursue further steps about the FDA’s decision if warranted.The company also said that it is evaluating the financial impact of the withdrawal of Ixchiq’s license in the U.S. However, it did not modify its revenue guidance. In the first half of 2025, Ixchiq contributed €7.5 million ($8.74 million) to the company’s €91 million total product sales.VALN stock is up by 116% this year and by about 18% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-exec-hints-at-possible-price-hike-on-model-y-in-us/chsssVVRdSR">Tesla Executive Hints At Possible Price Hike On Model Y In US: Retail Highlights Negative Catalysts</a>For updates and corrections, email newsroom[at]stocktwits[dot]comExchange Rate: €1= $1.16

An illustrative image of a person holding a medical syringe and a Covid-19 vaccine vial in front of the the Valneva logo displayed on a screen. On Wednesday, January 12, 2021, in Edmonton, Alberta, Canada. (Photo by Artur Widak/NurPhoto via Getty Images)

Valneva Stock Tumbles 19% After FDA Suspension Of Ixchiq License In US, Wall Street Divided On The Impact

While Jefferies lowered its price target on Valneva, H.C. Wainwright kept its $18 price target unchanged. 

Equity

While Jefferies lowered its price target on Valneva, H.C. Wainwright kept its $18 price target unchanged. 



Valneva (VALN) Soars 17.4%: Is Further Upside Left in the Stock?

Valneva (VALN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Valneva SE (VALN, $7.68) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

This indicator may be signaling that VALN's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Short Interest in Valneva SE (NASDAQ:VALN) Increases By 49.8%

Valneva SE (NASDAQ:VALN  Get Free Report) was the target of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 42,400 shares, an...

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Saint-Herblain (France), March 26, 2024 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the...

Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F

Saint-Herblain (France), March 25, 2024 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 22, 2024, of its 2023 Universal...

Valneva to Present on its Chikungunya Vaccine IXCHIQ , Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.

Saint-Herblain (France), March 21, 2024 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced it will present on its single-shot chikungunya vaccine, IXCHIQ...

Full Year 2023 Valneva SE Earnings Call Transcript

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older. The DUKORAL is a drinkable vaccine that helps prevent diarrhea caused by heat-labile toxin-producing ETEC, as well as cholera. The IXCHIQ is a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also offers additional vaccines, including VLA1553, VLA15, VLA160, VLA200, VLA1601 and others. Valneva was founded on May 28, 2013 and is headquartered in Saint-Herblain, France.

Valneva SE - ADR

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

Current Price	$9.28
Prev Close	$9.12
Open	$9.22
Dividend Yield	0.00%
50-Day Moving Average	$9.93
Beta	0.93
Avg. Volume	68,295.24
PE Ratio	-10.22

52-Week High	$12.25
52-Week Low	$3.62
Market Capitalization	$680.61M
EPS (Annual)	-$0.1818
Price to Book	3.38
Revenue Per Employee	$257,267.93
Enterprise Value/EBITDA	N/A

VALN
Valneva SE - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VALN News

VALNValneva SE - ADR